BACKGROUND: Randomized clinical trials have established the efficacy of an early invasive management strategy for high-risk non-ST elevation acute coronary syndromes (ACSs). We examined the use of in-hospital cardiac catheterization and medications in relation to risk across the broad spectrum of non-ST elevation ACSs. METHODS: We evaluated 4414 patients with non-ST elevation ACSs in the prospective, multicenter, Canadian ACS 1 (September 1, 1999-June 30, 2001) and ACS 2 (October 1, 2002-December 31, 2003) Registries. Patients were stratified into low-, intermediate-, and high-risk groups based on tertiles of the calculated Global Registry of Acute Coronary Events risk score (a validated predictor of in-hospital mortality). RESULTS: Although in-hospital mortality rates were similar, the in-hospital use of cardiac catheterization increased significantly over time (38.8% in the ACS 1 Registry vs 63.5% in the ACS 2 Registry; P<.001). The rates of cardiac catheterization in the low-, intermediate-, and high-risk groups were 48.0%, 41.1%, and 27.3% in the ACS 1 Registry, and 73.8%, 66.9%, and 49.7% in the ACS 2 Registry, respectively (P<.001 for trend for both). After adjusting for other confounders, intermediate-risk (adjusted odds ratio, 0.75; 95% confidence interval, 0.63-0.90; P<.001) and high-risk (adjusted odds ratio, 0.35; 95% confidence interval, 0.28-0.45; P<.001) patients remained less likely to undergo cardiac catheterization compared with low-risk patients. Furthermore, there existed a similar inverse relationship between risk and the use of in-hospital revascularization and medications. CONCLUSIONS: Despite temporal increases in the use of cardiac catheterization and revascularization in the management of non-ST elevation ACSs, evidence-based invasive and pharmacological therapies remain paradoxically targeted toward low-risk patients. Strategies to eliminate this treatment-risk paradox must be implemented to fully realize the benefits and optimize the cost-effectiveness of invasive management.
BACKGROUND: Randomized clinical trials have established the efficacy of an early invasive management strategy for high-risk non-ST elevation acute coronary syndromes (ACSs). We examined the use of in-hospital cardiac catheterization and medications in relation to risk across the broad spectrum of non-ST elevation ACSs. METHODS: We evaluated 4414 patients with non-ST elevation ACSs in the prospective, multicenter, Canadian ACS 1 (September 1, 1999-June 30, 2001) and ACS 2 (October 1, 2002-December 31, 2003) Registries. Patients were stratified into low-, intermediate-, and high-risk groups based on tertiles of the calculated Global Registry of Acute Coronary Events risk score (a validated predictor of in-hospital mortality). RESULTS: Although in-hospital mortality rates were similar, the in-hospital use of cardiac catheterization increased significantly over time (38.8% in the ACS 1 Registry vs 63.5% in the ACS 2 Registry; P<.001). The rates of cardiac catheterization in the low-, intermediate-, and high-risk groups were 48.0%, 41.1%, and 27.3% in the ACS 1 Registry, and 73.8%, 66.9%, and 49.7% in the ACS 2 Registry, respectively (P<.001 for trend for both). After adjusting for other confounders, intermediate-risk (adjusted odds ratio, 0.75; 95% confidence interval, 0.63-0.90; P<.001) and high-risk (adjusted odds ratio, 0.35; 95% confidence interval, 0.28-0.45; P<.001) patients remained less likely to undergo cardiac catheterization compared with low-risk patients. Furthermore, there existed a similar inverse relationship between risk and the use of in-hospital revascularization and medications. CONCLUSIONS: Despite temporal increases in the use of cardiac catheterization and revascularization in the management of non-ST elevation ACSs, evidence-based invasive and pharmacological therapies remain paradoxically targeted toward low-risk patients. Strategies to eliminate this treatment-risk paradox must be implemented to fully realize the benefits and optimize the cost-effectiveness of invasive management.
Authors: Merril L Knudtson; Colleen M Norris; P Diane Galbraith; Jaro Hubacek; William A Ghali Journal: Can J Cardiol Date: 2009-06 Impact factor: 5.223
Authors: S Jedrzkiewicz; S G Goodman; R T Yan; R C Welsh; J Kornder; J Paul DeYoung; G C Wong; B Rose; F R Grondin; R Gallo; W Huang; J M Gore; A T Yan Journal: Can J Cardiol Date: 2009-11 Impact factor: 5.223
Authors: Zach Rozenbaum; Sydney Benchetrit; Saar Minha; Yoram Neuman; Meital Shlezinger; Ilan Goldenberg; Morris Mosseri; David Pereg Journal: Cardiorenal Med Date: 2017-02-17 Impact factor: 2.041
Authors: Christian Widera; Michael J Pencina; Allison Meisner; Tibor Kempf; Kerstin Bethmann; Ivonne Marquardt; Hugo A Katus; Evangelos Giannitsis; Kai C Wollert Journal: Eur Heart J Date: 2011-12-23 Impact factor: 29.983
Authors: Mohammed Qintar; Kim G Smolderen; Paul S Chan; Kensey L Gosch; Philip G Jones; Donna M Buchanan; Saket Girotra; John A Spertus Journal: Am J Cardiol Date: 2017-07-14 Impact factor: 2.778
Authors: Shannon M Dunlay; Charanjit S Rihal; Thoralf M Sundt; Yariv Gerber; Véronique L Roger Journal: Curr Treat Options Cardiovasc Med Date: 2009-02
Authors: Khalid F Alhabib; Ahmad Hersi; Hussam Alfaleh; Khalid Alnemer; Shukri Alsaif; Amir Taraben; Tarek Kashour; Anas Bakheet; Ayed Al Qarni; Tariq Soomro; Asif Malik; Waqar H Ahmed; Ahmed M Abuosa; Modaser A Butt; Mushabab A Almurayeh; Abdulaziz Al Zaidi; Gamal A Hussein; Mohammed A Balghith; Tareg Abu-Ghazala Journal: J Saudi Heart Assoc Date: 2011-06-01
Authors: Khalid F AlHabib; Ahmad Hersi; Hussam AlFaleh; Mohammad Kurdi; Mohammad Arafah; Mostafa Youssef; Khalid AlNemer; Anas Bakheet; Ayed AlQarni; Tariq Soomro; Amir Taraben; Asif Malik; Waqar Habib Ahmed Journal: Can J Cardiol Date: 2009-07 Impact factor: 5.223